Molecular characterisation of cell line models for triple-negative breast cancers.
about
Long chain fatty Acyl-CoA synthetase 4 is a biomarker for and mediator of hormone resistance in human breast cancerOverexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-ANovel role of cannabinoid receptor 2 in inhibiting EGF/EGFR and IGF-I/IGF-IR pathways in breast cancer.Profiling the tyrosine phosphoproteome of different mouse mammary tumour models reveals distinct, model-specific signalling networks and conserved oncogenic pathways.Cell shape and the microenvironment regulate nuclear translocation of NF-κB in breast epithelial and tumor cells.Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of Cannabidiol in breast cancer.Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs.Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers.Metaplastic breast carcinomas display genomic and transcriptomic heterogeneity [corrected]. .Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant.Selective isolation and characterization of primary cells from normal breast and tumors reveal plasticity of adipose derived stem cells.Development and characterization of two human triple-negative breast cancer cell lines with highly tumorigenic and metastatic capabilities.Characterization of passive permeability at the blood-tumor barrier in five preclinical models of brain metastases of breast cancer.Breast cancer subtype dictates DNA methylation and ALDH1A3-mediated expression of tumor suppressor RARRES1Pharmacological levels of Withaferin A (Withania somnifera) trigger clinically relevant anticancer effects specific to triple negative breast cancer cellsDoubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-nessExpression of base excision repair key factors and miR17 in familial and sporadic breast cancerPIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.Dynamic architecture of the purinosome involved in human de novo purine biosynthesis.Identification of clinically predictive metagenes that encode components of a network coupling cell shape to transcription by image-omics.Glycoproteins in Claudin-Low Breast Cancer Cell Lines Have a Unique Expression Profile.Differences and homologies of chromosomal alterations within and between breast cancer cell lines: a clustering analysis.Lippia origanoides extract induces cell cycle arrest and apoptosis and suppresses NF-κB signaling in triple-negative breast cancer cells.Morphometric analysis of a triple negative breast cancer cell line in hydrogel and monolayer culture environments.Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer.TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase.Investigation on Physicochemical Characteristics of a Nanoliposome-Based System for Dual Drug Delivery.Activating Transcription Factor 3 as a Novel Regulator of Chemotherapy Response in Breast Cancer.Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK ActivationContribution of excision repair cross-complementing group 1 genotypes to triple negative breast cancer risk
P2860
Q16880225-34743FB9-E362-47AC-BC07-98B966BAA245Q17577870-FBD5564A-73D8-4F6B-A6E2-C204AF9ED8B4Q28872477-6F79CB75-BB53-46AC-8370-5C01BD4372E2Q52392673-CAC43BF1-B26C-4AF7-B7F3-E123AB353E54Q54798460-F3E75087-2DB0-4A6E-AE0F-7D1F1FE9F94DQ54798468-7F8C6D0C-95D9-4543-8CBC-6012461EBF90Q54798471-D4C99569-B9AA-45A2-9822-B9E638EEC14AQ54881530-B79D91E3-80A9-4426-82D4-57878DC97653Q54881536-90473C65-CB56-48F2-B2F7-6DA510B88477Q54881570-ABBE2008-8963-4860-9F0F-F74D02B587AFQ54881587-E9DB9DF7-6E74-47D4-BC2B-F0231F1AD713Q54881618-7516281A-E513-4105-8858-D1AE78BB26A0Q54881712-0B5E5CFC-4FD0-4CF7-9A04-EA9B820AAD02Q54881772-71432D10-9195-4230-B371-63F35DAE4B75Q54895774-5E52925E-75F0-48C6-9434-6472BF191335Q54904578-3E781FE5-6C27-4425-8642-7D9D7686BEBBQ54904639-204B5151-E047-4FE4-805F-A0EA99C72FC9Q54970827-8CC8D84D-3327-4AF3-B51D-F1B1EFC7D540Q54970832-7E2EC90D-D1BC-483B-9FF4-39B6DEC82F6FQ54970841-CD618AAA-1EB7-433C-991C-9367286224BBQ54970845-ADC23D2C-03D2-446B-9464-023FF4172BA1Q54970848-355CE96D-6C70-4E2B-84A5-AC1558029A79Q54971341-2C85C535-A11B-42B7-BA0D-A8DCA3010F7EQ54996119-543A18E7-98ED-4164-A6F9-9ACCB59AD430Q7390592-31BC31C9-CAC1-498D-816D-D859FB6CBFCD
P1343
Q21132473-A7ABB74E-BA92-4AAB-B811-920D5B1A27E9Q28828213-E007A6BF-B407-4CED-8E0D-518D76B67825Q33728086-B6A487B1-820F-4F7B-ADA4-DAF284DF1C17Q35000261-FE4E8135-801C-4291-9FD3-16671F601877Q35236726-38161366-7D97-4BA2-9F70-EC84A01921A9Q35287890-BC159445-5D74-4EFA-B192-5A1FA7FEE417Q35620990-D3887FAC-5131-4A9A-A917-330A2B3F70E3Q35812762-7C86D624-58DC-452E-B4DA-8227962E1307Q35911470-2DD28413-6678-428A-ABE1-3A70108DB4A3Q36289944-87C2997A-F3E2-44BB-AA45-457E4A7AA9E0Q36678970-0B57E270-68C4-465A-AEB9-FBE2691C31ADQ36706840-0F1323BE-FFA5-4FA6-8C02-2BA00615A237Q36721489-B370EC14-B87A-4C34-978F-4D894A562767Q37536796-E81337CB-6FC6-4190-8BD8-70FDD68A7949Q37548974-41A4EEB9-32E8-455C-97DD-8F0B2B67D919Q37584321-4EA53911-B553-47DA-9E1A-B3C6ADCE9E04Q37620662-D4271143-F6AA-408B-976A-42EF1C83FF47Q38735131-903EB456-CEA3-451E-AF48-A67A232D913FQ38925460-EB713B2F-27AE-438E-B464-F867A9C783BBQ39173155-3FF3699D-1382-46A6-A673-8F35E6A80994Q41411741-FC6EAE35-4615-4BBC-87D9-65E99527927CQ41916780-B788EE7C-09CC-4FF1-A8CF-EAF4B861B40DQ47099602-DCAC7AAD-C0F8-4FA0-9933-57CF1AE279DAQ50268380-149364DE-0BA9-4A2D-AAC2-CF23B113DF2AQ52726773-A6B363DF-D5F6-4887-890B-6C2033A7C493Q53090999-FAB0989A-8300-4282-B931-EDC93E6C979BQ55207437-7BF383CF-2016-44FF-9672-033230B262A6Q55646151-1E1621C4-A1E0-4D3A-91D0-51661882F8A5Q58721369-9BF21046-B229-4ED1-B29C-686586200FE6Q58791244-AB27C368-D1EE-4C3E-82AE-5B5705B921CC
P2860
Molecular characterisation of cell line models for triple-negative breast cancers.
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Molecular characterisation of cell line models for triple-negative breast cancers.
@ast
Molecular characterisation of cell line models for triple-negative breast cancers.
@en
Molecular characterisation of cell line models for triple-negative breast cancers.
@nl
type
label
Molecular characterisation of cell line models for triple-negative breast cancers.
@ast
Molecular characterisation of cell line models for triple-negative breast cancers.
@en
Molecular characterisation of cell line models for triple-negative breast cancers.
@nl
prefLabel
Molecular characterisation of cell line models for triple-negative breast cancers.
@ast
Molecular characterisation of cell line models for triple-negative breast cancers.
@en
Molecular characterisation of cell line models for triple-negative breast cancers.
@nl
P2093
P2860
P4510
P356
P1433
P1476
Molecular characterisation of cell line models for triple-negative breast cancers.
@en
P2093
Alan Mackay
Andrew Tutt
Anita Grigoriadis
Elodie Noel
Jessica Frankum
Pei Jun Wu
Rachel Natrajan
P2860
P2888
P356
10.1186/1471-2164-13-619
P407
P577
2012-11-14T00:00:00Z
P5875
P6179
1046480543